Edwards Lifesciences Corp
ISIN US28176E1082
|WKN 936853
Market cap (in EUR)
38,885.64 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Healthcare Healthcare Equipment General Medical Devices United States
Financials
Key metrics
| Market capitalisation, EUR | 38,885.64 m |
| EPS, EUR | 2.31 |
| P/B ratio | 4.45 |
| P/E ratio | 30.51 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 5,028.68 m |
| Net income, EUR | 1,295.10 m |
| Profit margin | 25.75% |
What ETF is Edwards Lifesciences Corp in?
There are 395 ETFs which contain Edwards Lifesciences Corp. All of these ETFs are listed in the table below. The ETF with the largest weighting of Edwards Lifesciences Corp is the VanEck Bionic Engineering UCITS ETF A.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
